THE BRAIN ON CANNABIS AUTHOR | REBECCA SIEGEL, M.D.



On this episode of Let’s be Blunt Montel talks with Dr. Rebecca Siegel, the author of the newly published book, The Brain on Cannabis: What You Should Know about Recreational and Medical Marijuana. Dr. Siegel is a clinical psychiatrist specializing in adult, child and adolescent psychotherapy and psychopharmacology. Her practice includes the evaluation and treatment of depression, mood disorders, attention deficit disorders, learning disabilities, Aspergers and autism spectrum disorder and she is a licensed prescriber of medical cannabis in New York State. Her book includes tips on how to effectively talk to young people about recreational cannabis as well as addressing common myths surrounding cannabis.
#cannabiscommunity #cannabiseducation #cannabis #cannabisculture

Subscribe: https://www.youtube.com/channel/UCMGyFAMo_k-0Q7Ui9DXCCmQ?sub_confirmation=1

Learn more about Montel Williams and his show: https://letsbebluntmontel.com/

FOLLOW MONTEL
• Facebook – https://www.facebook.com/MontelWilliamsFan/
• Twitter – https://twitter.com/Montel_Williams?s=20
• Instagram – https://www.instagram.com/letsbebluntmontel/?hl=en

For Montel’s FREE THINKING Channel GoTo
https://www.youtube.com/channel/UCIPA9h9AFaYoFrC-45MS2IQ

source

Please follow and like us:
Pin Share

By admin

10 thoughts on “THE BRAIN ON CANNABIS AUTHOR | REBECCA SIEGEL, M.D.”
  1. I am loving this so educational. I am in a cannabis certification course currently. It is in my nursing program . I am working towards my NP. One of the things I notice is how much worry there is around some of the potential side effects of cannabis. While I agree that it is important to understand the potential side effects as you would with any medication, it is hard not to recognize all the medications that are used particularly in the psychiatric arena , that literally suck the life essence out of people. I do not see the years of caution and deliberation over these medications. The protocol is to just throw another medication on board.

    The risk profile for cannabis is so incredibly low. Every person I hear speak on it , every presentation , every research article that comes out of the medical world is full of caveats and warnings. They read something like this…

    Yes there is all this potential and anecdotally … The evidence is robust BUT … Xyz to be fearful of.

    But if your too scared … We can give you Xanax … Valium … Pick your poison…. But this plant right here … Caution

    We all know why this is happening. It has nothing to do with risk profiles. It has to do with the use of this medicine is going to reduce the need for some of the big money makers.

  2. In the psychedelic / ketamine arena there is the " guide " that is educated and vetted to sit with the person as they experience the psychoactive component. I think this would be a good approach with cannabis naive users the first or for several times.

    This can be a time of observation and reporting as well as education for the new patient.

  3. I do have some ideas around how the dispensary bud tenders and myriad experts within in the field of cannabis become part of an interdisciplinary team that works with the licensed person , who by many accounts has a greater restraint on what they can council a patient who would like to explore cannabis. However the unlicensed person's do not have those restrictions around a " license". Educate the patient … Work collaboratively with the dispensary unlicensed person's.

    So the medical person who has to worry about infringement on licensure , as well as AMA and pharmaceutical backlash can work within those constraints and scope.

    Essentially stay away from
    " prescribing ". Educate so robustly that the patient becomes an expert in their own healthcare.

    Actually this could work in all healthcare.

  4. HYPER-H21-4 is expected to consist of 60 volunteers between the ages of 45-70 using three 150 mg doses of DehydraTECH-CBD, every day for the 6-week duration of the study. The study will use a double blinded, randomized cross-over design, and a placebo control. Some volunteers will already be using leading standard of care hypertension drugs such as ACE inhibitors with or without diuretics which will help evaluate the efficacy of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study will allow Lexaria to gather critical data monitoring of DehydraTECH-CBD over time and will evaluate the potential for longer term health benefits.

    HYPER-H21-4 is more comprehensive than any work previously undertaken by Lexaria and many types of analysis will be performed including 24-hour ambulatory blood pressure (the primary outcome); arterial stiffness and autonomic balance; brain structure and function through brain magnetic resonance imaging ("MRI"); blood biomarkers (including lipids such as cholesterol and more); renal, hepatic, sleep quality / daytime sleepiness / sleep disorders; actigraphy, geriatric depression scale, perceived stress, and Beck anxiety inventory. The wide range of data collection could provide additional insights into the long-term health benefits of DehydraTECH-CBD that might otherwise remain undetected

  5. Dehydratech.. Effects felt in minutes.. Lower doses..no sweeteners due to masking unwanted taste.. Great for both the pharmaceutical and recreational markets.. 60 patient study due out with 60 days

  6. Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others.

  7. Premier conducted a global competition to evaluate the world's most advanced molecule delivery technologies, and selected Lexaria's DehydraTECH technology based on its superior performance and the extensive data available through Lexaria's years of testing," said Shinji Shosoyama, CEO of Premier.

    "Lexaria is delighted to be working with Premier Wellness Science which we expect will dominate the newly opening Japanese market for CBD-based products," said Chris Bunka, CEO of Lexaria. "Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer's needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets."

Comments are closed.

RSS
Follow by Email